对黄血蚕制品-金蚕宝制剂系列的保健作用研究表明:金蚕宝降脂I号表现出极显著降低高血脂模型小鼠血清总胆固醇(TC)和血清甘油三脂(TG)的效果(P<0.01),并在一定剂量范围内显示出明显的剂量效应关系;金蚕宝降糖制剂可显著改善四氧嘧啶诱导的糖尿病小鼠三多一少的症状及降低血糖值,其中饲料消耗量、饮水量和尿量分别降低25%、47%和43%,并能维持体重,血糖值在对照组上升56%的状况下降低33%(P<0.01);研究微粉化后的蚕粉末对糖尿病的治疗效果和剂量,改进剂型比原剂型生物利用度提高一倍,且降糖效果(50.47%)显著优于格列本脲(34.63%)(P<0.05);对家蚕熟蚕粉和灵芝为主要材料的金蚕宝护肝制剂(JCBH)研究表明,金蚕宝护肝制剂和熟蚕粉均显著降低小鼠血中谷丙转氨酶(ALP)和谷草转氨酶(AST)的酶活力(P<0.01),金蚕宝护肝制剂略优于熟蚕粉,但与阳性药联苯双酯和熟蚕粉相比,无显著性差异(P>0.05)。研究结果表明黄血蚕具有较高的保健作用。 The research on the health effects of the Huangxue silkworm product-Jinbibao preparation series showed that: Jinyingbao Jiangzhi I showed extremely significant effects in reducing serum total cholesterol (TC) and serum triglyceride (TG) in mice with hyperlipidemia. (P <0.01), and showed a significant dose-effect relationship within a certain dose range; Jin Sibao hypoglycemic agent can significantly improve the symptoms of alloxan-induced diabetic mice and reduce the blood sugar level, including feed Consumption, drinking water, and urine output decreased by 25%, 47%, and 43%, respectively, and the body weight was maintained. The blood sugar level decreased by 33% (P<0.01) when the control group increased by 56% (P<0.01); the micronized silkworm was studied. The therapeutic effect and dose of powder on diabetes mellitus improved the bioavailability of the original dosage form by a factor of two, and the hypoglycemic effect (50.47%) was significantly better than glyburide (34.63%) (P<0.05); Research on JCBH (Jinbabao Hugan Preparations) using powdered powder and Ganoderma lucidum as the main materials showed that the Golden Silkworm Liver Preparation and the Mature Silkworm Powder significantly reduced the enzyme activity of alanine aminotransferase (ALP) and aspartate aminotransferase (AST) in mice blood. (P<0.01), Jin Sibao Hugan Preparation slightly better than mature silkworm powder, but compared with the positive drug biphenyl diester and mature silkworm powder, No significant difference (P>0.05). The results show that the yellow bloodworm has a higher health care effect.